TransMedics Group is a commercial-stage medical technology company that developed the Organ Care System (OCS), a portable organ perfusion and monitoring platform used for lung, heart, and liver transplants. Its shares carry a "Buy" consensus among the roughly 13 analysts tracked, with most ratings split between Strong Buy and Buy and a smaller Hold contingent.
The central $100 target is the arithmetic mean of the firm's current price targets, which aggregators place near $99 before rounding. Individual targets reviewed range from about $70 on the cautious end to roughly $125 on the bullish end, a wide spread that reflects genuine disagreement over how much the company's growth can offset execution and margin concerns. Post-earnings, Canaccord Genuity's William Plovanic raised his target to $120 and kept a Buy rating, while Baird lifted its target to $117 with an Outperform rating and Needham maintained Buy with a $110 target. On the more cautious side, JPMorgan raised its target to $85 but kept a Neutral rating, and Stifel held at $70 with a Hold. These figures are individual analyst expectations, not a guarantee, and they differ because analysts weight margin durability, competition, and valuation differently.
With shares at $88.24, reaching $100 would require an advance of about 13%, a modest-to-substantial move given the stock's volatility (its 52-week range spans $60.11 to $156.00). The shares jumped roughly 28% in a single session after the company's November 5, 2026 earnings report, recovering sharply from a recent low near $60 but remaining well below the prior $156 high.
The path toward the target depends on whether the company can sustain transplant procedure growth and logistics momentum while repairing margins. Q3 revenue of $203 million beat consensus of roughly $178 million, and adjusted EPS (earnings per share) of $0.51 exceeded expectations near $0.30. Management's raised full-year guidance of $764 million–$774 million signals continued momentum, but the stock's forward P/E (price-to-earnings ratio) remains elevated, meaning execution must stay on track to justify further appreciation.
Technically, TMDX is in a recovery phase after a deep drawdown. The $100 mark is a psychologically significant round number that also sits just above the post-earnings gap, making it a natural resistance area. Below, the $76–$79 zone marks the recent breakout and gap area, a potential support level, while $60.11 is the 52-week low. The $156 52-week high represents a much more distant overhead level. Because the stock is well off its peak, overhead supply from earlier buyers could slow any sustained advance toward and beyond $100.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms vary. Investors should watch the company's next quarterly earnings and guidance, any resolution or update on the internal-controls weakness, margin trends, transplant procedure and flight volume data, and further analyst target revisions. Additional catalysts include progress on European logistics contracts and any developments in the pipeline of organ programs, as well as broader sentiment toward high-growth medical technology stocks.
AI Daily Buy/Sell Signals is a Tickeron tool that uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than replacing research, it is designed to help traders discover new opportunities, keep an eye on existing positions, and spot changing trends more efficiently than manual scanning. For those following a volatile name like TMDX, these automated signals can provide an additional, objective layer of insight alongside fundamental and technical work.
Can TransMedics Group reach $100? The central target, derived from the mean of current analyst price targets, sits about 13% above the latest price — a plausible but not assured objective following a powerful earnings-driven rally. The bull case rests on strong transplant procedure growth, surging logistics revenue, raised guidance, and European expansion. The bear case centers on margin pressure, the disclosed internal-controls weakness, softer flight trends, and a demanding valuation. With analyst targets spanning roughly $70 to $125, the wide dispersion underscores genuine uncertainty. The next earnings report, margin trajectory, and any internal-controls developments will be the clearest signposts for whether shares can hold their gains and advance toward the target. No outcome is guaranteed, and investors should weigh both the upside and the risks.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TMDX has been loosely correlated with ATEC. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if TMDX jumps, then ATEC could also see price increases.
| Ticker / NAME | Correlation To TMDX | 1D Price Change % | ||
|---|---|---|---|---|
| TMDX | 100% | -3.03% | ||
| ATEC - TMDX | 37% Loosely correlated | -5.15% | ||
| RDNT - TMDX | 35% Loosely correlated | -0.56% | ||
| SMTI - TMDX | 34% Loosely correlated | -1.37% | ||
| ALGN - TMDX | 33% Loosely correlated | N/A | ||
| PODD - TMDX | 32% Poorly correlated | -1.17% | ||
More | ||||
| Ticker / NAME | Correlation To TMDX | 1D Price Change % |
|---|---|---|
| TMDX | 100% | -3.03% |
| Health Services category (239 stocks) | 8% Poorly correlated | -1.13% |
| Medical/Nursing Services category (138 stocks) | 8% Poorly correlated | -1.46% |